Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411309 | 0.91 | ESR1 (0.35) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL31411460 | 0.86 | ESR1 (0.41) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL31411343 | 0.81 | ESR1 (0.38) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL19249525 | 0.79 | ESR1 (0.42) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL28348643 | 0.77 | ESR1 (0.42) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL19204856 | 0.77 | ESR1 (0.42) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL31411438 | 0.77 | CYP4F2 (0.34) | CYP4F2CYP4A11EGFR | |
| SCHEMBL31411414 | 0.76 | HTR1A (0.38) | CYP4F2CYP4A11HTR6ATREGFR | |
| SCHEMBL31411379 | 0.74 | ESR1 (0.40) | ESR1CYP4F2CYP4A11ALDH1A1ATR | |
| SCHEMBL19204873 | 0.72 | ESR1 (0.40) | ESR1CYP4F2CYP4A11ALDH1A1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | ESR1 3008/4885CYP4F2 614/4885CYP4A11 1465/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | ESR1 3008/4885CYP4F2 614/4885CYP4A11 1465/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | ESR1 3008/4885CYP4F2 614/4885CYP4A11 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.